Neratinib
Brand: Nerlynx (global)
Anticancer
HER2 irreversible TKI
Pharmacokinetics
| Half-life | 17 hours |
| Tmax | 7 h |
| Protein Binding | 99 % |
| Volume of Distribution | 643 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Very high diarrhoea risk → mandatory anti-diarrhoeal prophylaxis during first 1–2 months. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Severe diarrhoea, hepatotoxicity, nausea, stomatitis
Contraindications:
Severe hepatic impairment
Precautions:
Start loperamide prophylaxis with initiation; monitor LFTs regularly.